Intraocular pressure increased adverse event reports that record this term

Kind of term: MedDRA preferred term
Plain meaning: raised pressure in the eye

What a report is

A report is not proof that the drug was the cause of the event.

FDA says:

Adverse event reports submitted to FDA do not undergo extensive validation or verification. Therefore, a causal relationship cannot be established between product and reactions listed in a report. While a suspected relationship may exist, it is not medically validated and should not be the sole source of information for clinical decision making or other assumptions about the safety or efficacy of a product. Additionally, it is important to remember that adverse event reports represent a small percentage of total usage numbers of a product. Common products may have a higher number of adverse events due to the higher total number of people using the product.
Source: openFDA, Drug Adverse Event Overview, section "Responsible use of the data". The site read the page on 2 Oct 2026. The data have the reports that FDA received through 30 Jun 2026.

FDA also says:

There is no certainty that the reported event (adverse event or medication error) was actually due to the product. FDA does not require that a causal relationship between a product and event be proven, and reports do not always contain enough detail to properly evaluate an event. The information in these reports has not been scientifically or otherwise verified as to a cause and effect relationship and cannot be used to estimate the incidence of these events.
Source: openFDA, Drug Adverse Event Overview. The site read the page on 2 Oct 2026.

Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated.
Source: openFDA, Response of the drug event API (meta.disclaimer). The site read the page on 2 Oct 2026.

Not medical advice. This site counts what was reported to FDA. Questions about a medicine or device belong with a pharmacist or clinician.

Reports on file

From January 2004 to June 2026, FDA received 12,661 adverse event reports that record the MedDRA preferred term Intraocular pressure increased. In plain words, the term means: raised pressure in the eye. The person who codes a report selects the term that agrees best with the description of the reporter.

FDA received 564 reports in the 12 months to June 2026 and 589 in the 12 months before. FDA releases FAERS data every quarter, so the newest months are not complete. They grow in later releases.

By reports in the 12 months to June 2026, this term was number 921 of 1,436 reaction terms with a page. Of the 1,332,454 drug reports that FDA received in the 12 months to June 2026, 564 (under 0.1%) record this term. Reports for patients aged 18 to 44 were 7.4% of the reports that record this term and 12.3% of all drug reports.

The number of people who use the product is not in the data. A count is not a rate.

MedDRA

The Medical Dictionary for Regulatory Activities. The person who codes a report selects the preferred term that agrees best with the description of the reporter. FDA does not publish the description.

Plain meaning

Raised pressure in the eye. The words are from the fixed dictionary of this site. They add nothing to a report.

Data version

openFDA FAERS release of 29 Oct 2026. Reports received through 30 Jun 2026.

Drugs in these reports

The table has the 105 drug pages with 25 or more reports that record this term. The rows are in order of name. A drug page with fewer reports for this term is not in the table. The counts are the counts that the site keeps for each reaction term, and a count can be lower than the count of FDA.

FDA says:

Additionally, it is important to remember that adverse event reports represent a small percentage of total usage numbers of a product. Common products may have a higher number of adverse events due to the higher total number of people using the product.
Source: openFDA, Drug Adverse Event Overview. The site read the page on 2 Oct 2026.

Importantly, the AEMS data by themselves are not an indicator of the safety profile of the drug or biologic.
Source: FDA, FDA Adverse Event Monitoring System (AEMS) Public Dashboard. Content current as of 11 Mar 2026. The site read the page on 2 Oct 2026.

Drugs that the reports with the term Intraocular pressure increased name as a suspect product, in order of name
Drug	Class	Reports with this term
Acetazolamide	Carbonic anhydrase inhibitor	72
Actemra	Interleukin-6 receptor antagonist	34
Advair Diskus 100/50		37
Alphagan		28
Alphagan P	alpha-Adrenergic agonist	204
Amphotericin b	Lipid-based polyene antifungal	60
Arava	Antirheumatic agent	32
Aspirin	Nonsteroidal anti-inflammatory drug	27
Avastin	Vascular endothelial growth factor inhibitor	161
Azopt	Carbonic anhydrase inhibitor	175
Beovu		98
Bevacizumab	Vascular endothelial growth factor inhibitor	104
Bimatoprost	Prostaglandin analog	25
Brimonidine	alpha-Adrenergic agonist	130
Brimonidine tartrate	alpha-Adrenergic agonist	49
Brinzolamide	Carbonic anhydrase inhibitor	34
Bss	Osmotic laxative	26
Ceftazidime	Cephalosporin antibacterial	61
Cialis	Phosphodiesterase 5 inhibitor	37
Ciprofloxacin	Fluoroquinolone antibacterial	67
Colistin		61
Combigan	alpha-Adrenergic agonist	204
Corticotropin		33
Cosopt	Carbonic anhydrase inhibitor	92
Cosopt Pf	Carbonic anhydrase inhibitor	28
Cymbalta		69
Dexamethasone	Corticosteroid	146
Dexamethasone Tobramycin		32
Diovan	Angiotensin 2 receptor blocker	36
Dorzolamide	Carbonic anhydrase inhibitor	43
Dorzolamide hydrochloride	Carbonic anhydrase inhibitor	29
Dupixent	Interleukin-4 receptor alpha antagonist	122
Durezol		486
Durysta	Prostaglandin analog	60
Enbrel	Tumor necrosis factor blocker	146
Eylea	Vascular endothelial growth factor inhibitor	643
Eylea Hd	Vascular endothelial growth factor inhibitor	60
Forteo	Parathyroid hormone analog	29
Gilenya	Sphingosine 1-phosphate receptor modulator	83
Humira		448
Hydroxychloroquine	Antimalarial	33
Iluvien	Corticosteroid	170
Infliximab	Tumor necrosis factor blocker	33
Latanoprost	Prostaglandin analog	497
Latanoprost ophthalmic solution 0.005%	Prostaglandin analog	53
Lidocaine	Amide local anesthetic	25
Linezolid	Oxazolidinone antibacterial	65
Lipitor	HMG-CoA reductase inhibitor	32
Lotemax	Corticosteroid	50
Lucentis	Vascular endothelial growth factor inhibitor	281
Lumigan	Prostaglandin analog	433
Lumigan 0 01%		55
Lyrica		81
Maxidex	Corticosteroid	84
Methotrexate	Folate analog metabolic inhibitor	108
Methylprednisolone	Corticosteroid	57
Moxifloxacin	Fluoroquinolone antibacterial	55
Moxifloxacin hydrochloride	Fluoroquinolone antibacterial	34
Mycophenolate mofetil	Antimetabolite immunosuppressant	82
Nasonex	Corticosteroid	32
Orencia	Selective T cell costimulation modulator	26
Oxervate		66
Ozurdex	Corticosteroid	216
Piperacillin sodium,tazobactam sodium		27
Pred Forte	Corticosteroid	59
Prednisolone	Corticosteroid	171
Prednisolone acetate	Corticosteroid	99
Prednisolone sodium phosphate	Corticosteroid	61
Prednisone	Corticosteroid	209
Prolia	RANK ligand inhibitor	32
Ranibizumab	Vascular endothelial growth factor inhibitor	109
Remicade	Tumor necrosis factor blocker	46
Restasis	Calcineurin inhibitor immunosuppressant	69
Revlimid	Thalidomide analog	39
Rhopressa		64
Rinvoq	Janus kinase inhibitor	35
Rituximab	CD20-directed cytolytic antibody	35
Simbrinza	Carbonic anhydrase inhibitor	144
Stelara	Interleukin-12 antagonist	26
Sulfasalazine	Aminosalicylate	38
Syfovre	Complement inhibitor	48
Symbicort	Corticosteroid	35
Tacrolimus	Calcineurin inhibitor immunosuppressant	105
Timolol	beta-Adrenergic blocker	115
Timolol maleate	beta-Adrenergic blocker	126
Timoptic	beta-Adrenergic blocker	31
Tiotropium bromide	Anticholinergic	86
TobraDex	Aminoglycoside antibacterial	65
Tobramycin	Aminoglycoside antibacterial	72
Topamax		63
Topiramate		72
Travatan		131
Travatan Z	Prostaglandin analog	192
Travoprost	Prostaglandin analog	44
Triamcinolone		51
Triamcinolone acetonide	Corticosteroid	123
Trusopt		33
Vabysmo		129
Vancomycin	Glycopeptide antibacterial	45
Vancomycin hydrochloride	Glycopeptide antibacterial	30
Voriconazole	Azole antifungal	64
Vyzulta		54
Xalatan	Prostaglandin analog	949
Xeljanz	Janus kinase inhibitor	33
Zioptan	Prostaglandin analog	70

The page of each drug has the count of each reaction term in its reaction lookup.

Drug classes in these reports

The table has the 51 pharmacologic classes with 25 or more reports that record this term. The rows are in order of name.

FDA says:

Additionally, it is important to remember that adverse event reports represent a small percentage of total usage numbers of a product. Common products may have a higher number of adverse events due to the higher total number of people using the product.
Source: openFDA, Drug Adverse Event Overview. The site read the page on 2 Oct 2026.

Importantly, the AEMS data by themselves are not an indicator of the safety profile of the drug or biologic.
Source: FDA, FDA Adverse Event Monitoring System (AEMS) Public Dashboard. Content current as of 11 Mar 2026. The site read the page on 2 Oct 2026.

Pharmacologic classes of the drugs that the reports with the term Intraocular pressure increased name, in order of name
Class	Reports with this term
Alkylating drug	28
alpha-Adrenergic agonist	587
Amide local anesthetic	47
Aminoglycoside antibacterial	139
Aminosalicylate	59
Angiotensin 2 receptor blocker	75
Anticholinergic	150
Antimalarial	47
Antimetabolite immunosuppressant	87
Antirheumatic agent	51
Atypical antipsychotic	66
Azole antifungal	64
Benzodiazepine	49
beta-Adrenergic blocker	289
beta3-Adrenergic agonist	27
Calcineurin inhibitor immunosuppressant	205
Carbonic anhydrase inhibitor	658
CD20-directed cytolytic antibody	58
Cephalosporin antibacterial	103
Complement inhibitor	53
Corticosteroid	1,667
Fluoroquinolone antibacterial	200
Folate analog metabolic inhibitor	132
GLP-1 receptor agonist	51
Glycopeptide antibacterial	75
HMG-CoA reductase inhibitor	66
Insulin analog	46
Integrin receptor antagonist	35
Interleukin-12 antagonist	26
Interleukin-4 receptor alpha antagonist	135
Interleukin-6 receptor antagonist	38
Janus kinase inhibitor	77
Kinase inhibitor	72
Lipid-based polyene antifungal	60
Nonsteroidal anti-inflammatory drug	109
Osmotic laxative	33
Oxazolidinone antibacterial	65
P2Y12 platelet inhibitor	33
Parathyroid hormone analog	29
Phosphodiesterase 5 inhibitor	82
Prostaglandin analog	2,296
Purine antimetabolite	30
RANK ligand inhibitor	38
Selective T cell costimulation modulator	26
Serotonin and norepinephrine reuptake inhibitor	41
Serotonin reuptake inhibitor	55
Sphingosine 1-phosphate receptor modulator	85
Thalidomide analog	41
Tumor necrosis factor blocker	290
Vascular endothelial growth factor inhibitor	1,382
Vitamin K antagonist	39

A class with many reports in all has many reports for almost every term.

Reports by month

Reports that record Intraocular pressure increased, by month, five years to June 2026

FDA releases FAERS data every quarter, so the newest months are not complete. They grow in later releases.

Patients in these reports

Age of the patient in the reports that record Intraocular pressure increased
Age	Reports	Share
Under 2	34	0.3%
2 to 11	209	1.7%
12 to 17	161	1.3%
18 to 44	937	7.4%
45 to 64	1,982	15.7%
65 to 74	1,659	13.1%
75 and over	1,583	12.5%
Age not given	6,096	48.1%

Sex of the patient in the reports that record Intraocular pressure increased
Sex	Reports	Share
Female	6,396	50.5%
Male	4,163	32.9%
Unknown or not given	2,102	16.6%

Age and sex are as the report gives them. 57.6% of these reports give the United States as the country.

Terms near this one

These are the next terms in the A to Z list. The links are for navigation.

Official pages

MedWatch Online Voluntary Reporting FormThe online form of FDA for a voluntary report.
MedWatch: The FDA Safety Information and Adverse Event Reporting ProgramThe page of the FDA program that receives reports about drugs and devices.
FDA Adverse Event Monitoring System (AEMS) Public DashboardThe public dashboard of FDA for adverse event reports on drugs and biologics.

The site checked these addresses on 2 Oct 2026. The links open in a new tab.

Cite this page

Reported Reactions. Intraocular pressure increased: adverse event reports that record this term. https://reportedreactions.com/reaction/intraocular-pressure-increased/ Source: U.S. Food and Drug Administration, openFDA Drug Adverse Event (FAERS) files, release of 29 Oct 2026. Reports received through 30 Jun 2026.

Where the data come from

The counts come from the openFDA Drug Adverse Event (FAERS) bulk files, release of 29 Oct 2026. The files have the reports that FDA received through 30 Jun 2026. A drug name is the name on the report. The site matches it to a brand name or a generic name of the National Drug Code Directory of 2 Nov 2026. A class is the pharmacologic class (EPC) of the FDA label.

The count has the reports with each spelling of one MedDRA preferred term. The site does not publish a report narrative, a lot number, a detail of a patient or the identity of a reporter. The record of FDA is the authority. See how the site counts reports, the data sources and the corrections page.

Questions

What does Intraocular pressure increased mean in an adverse event report?

In plain words: raised pressure in the eye. It is a MedDRA preferred term. FDA codes the description of a reporter with the MedDRA dictionary. The openFDA files do not have the description itself, and this site does not show it.

Does a drug in the table mean that the drug was responsible for this reaction?

No. FDA says:

No individual drug is connected to any individual reaction.
Source: openFDA, Drug Adverse Event Overview. The site read the page on 2 Oct 2026.

When a report lists multiple drugs and multiple reactions, there is no way to conclude from the data therein that a given drug is responsible for a given reaction.
Source: openFDA, Drug Adverse Event Overview. The site read the page on 2 Oct 2026.

What does this page tell a person who has this symptom?

This page gives counts of reports. It cannot assess a person. A pharmacist or a clinician can assess a person.

If this is a medical emergency, please call 911.
Source: FDA, MedWatch Online Voluntary Reporting Form. The site read the page on 2 Oct 2026.

To the top of the page